Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 419Precursor Cell Lymphoblastic Leukemia-Lymphoma 126Neoplasms, Plasma Cell 74Recurrence 70Lymphoma 57Leukemia 54Neoplasms 46Immunoglobulin Light-chain Amyloidosis 38Burkitt Lymphoma 37Vomiting 36Lymphoma, Mantle-Cell 32Lymphoma, Large B-Cell, Diffuse 31Nausea 29Lymphoma, Non-Hodgkin 28Breast Neoplasms 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 21Hodgkin Disease 21Leukemia, Lymphocytic, Chronic, B-Cell 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasm Metastasis 17Prostatic Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Amyloidosis 16Leukemia, Myeloid, Acute 15Smoldering Multiple Myeloma 14Lymphoma, B-Cell, Marginal Zone 13Lung Neoplasms 11Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell 10

Interventions

Cisplatin 3sodium thiosulfate 2Acetylcysteine 2Vorinostat 1Surveys and Questionnaires 1Radiosurgery 1Pantoprazole 1Methotrexate 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Hearing Tests 1Genetic Association Studies 1Dexamethasone 1Audiometry 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ototoxicity × Dexamethasone × Clear all
NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ohio State University Comprehensive Cancer Center

Phase NA Withdrawn

Ototoxicity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡